Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better Outcomes in Opioid Use Disorder
ARPA-H seeks early-stage clinical trial proposals to rigorously evaluate ibogaine’s safety and effectiveness as a treatment for opioid use disorder.
Funder: Advanced Research Projects Agency for Health
Due Dates: October 15, 2026: Solution Summary submission deadline
Funding Amounts: Funding amount not specified; ARPA-H typically supports multi-million dollar, milestone-driven early-stage clinical trials.
Summary: Supports rigorous early-stage clinical trials of ibogaine as a potential treatment for opioid use disorder, aiming to generate evidence for safety and effectiveness.
Key Information: Solution Summaries must be submitted via the ARPA-H Solutions portal; teaming is encouraged.
Description
The Advanced Research Projects Agency for Health (ARPA-H) is seeking innovative proposals for early-stage clinical trials evaluating the safety and effectiveness of ibogaine as a treatment for opioid use disorder (OUD). With over 5 million Americans affected by OUD and a continued need for new therapeutic options, this initiative aims to close the evidence gap for ibogaine and similar neuroplastogen-based interventions. Selected projects will emphasize patient safety, scientific rigor, and the potential for rapid translation into later-phase clinical testing, directly addressing the opioid crisis by expanding the range of effective treatments.
